anti-vegf

Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).

Anti-VEGF Antibody is a human antibody expressed in CHO cells, targeting VEGF. It features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.5 kDa. For its isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a κ monoclonal antibody that binds mouse VEGF-A with high affinity, functioning as a potent VEGF-A inhibitor. Anti-Mouse VEGF-A Antibody demonstrates significant antitumor activity in gastric cancer xenograft models, supporting its relevance in angiogenesis blockade studies, tumor microenvironment research, and preclinical evaluation of VEGF-targeted therapies.

Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a human antibody expressed in CHO cells, specifically targeting VEGFR2/KDR/CD309. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For an isotype control, refer to HumanIgG4kappa, Isotype Control.

Anti-VEGFR1/FLT1 Antibody is a humanized antibody expressed in CHO cells, targeting VEGFR1/FLT1. It features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-VEGFR2/KDR/CD309 Antibody is a human-derived antibody expressed in CHO cells, targeting VEGFR2/KDR/CD309. This antibody features a muIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For its isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-VEGF165/VEGFA Antibody (4A225) is a Rabbit IgG monoclonal antibody targeting Human, Cynomolgus VEGF165/VEGFA.

Anti-VEGF165/VEGFA Antibody (5L924) is a Rabbit IgG monoclonal antibody targeting Human, Cynomolgus VEGF165/VEGFA.

Vanucizumab is a bispecific humanised monoclonal antibody that simultaneously inhibits the receptor interactions of VEGF-A and Angiopoietin-2 (Ang-2), exhibiting anti-angiogenic and anti-cancer effects, and can be used for the treatment of advanced solid tumours.

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody that can be combined with Paclitaxel for cancer research, particularly in studies of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3].

Abicipar pegol (AGN-150998, MP0112), an anti-VEGF DARPin molecule, is a novel class of small ankyrin repeat domain-containing proteins designed for high specificity and affinity targeting. This compound effectively inhibits angiogenesis and vascular permeability, and has been applied in ocular inflammation-related disease studies through intravitreal injections, significantly reducing mean retinal thickness and leakage area [1] [2].

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, used for the treatment of non-small cell lung cancer (NSCLC).

Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).

DX-2240 is a human monoclonal antibody (mAb) that targets TIE1. It can inhibit tumor growth and render the tumor vasculature sensitive to anti-angiogenic agents (VEGF pathway inhibitors).

AG01 is a monoclonal antibody targeting the anti-granular protein precursor (GP88). It inhibits the proliferation and migration of triple-negative breast cancer (TNBC) cells, reducing the expression of phosphorylated protein kinases such as p-Src, p-AKT, and p-ERK, as well as oncogenic proteins like Axl, c-MET, HIF-1α, and VEGF. In TNBC xenograft mouse models, AG01 suppresses tumor growth and the expression of Ki67 in vivo. AG01 is useful for research involving cancers like TNBC.

Anti-Mouse VEGFR-2 Antibody (DC101) is a rat-derived monoclonal antibody against mouse VEGFR2/KDR/Flk-1, serving as a mouse analogue of ramucirumab. It induces tumour cell apoptosis by blocking VEGF-VEGFR binding and inhibiting tumour angiogenesis, suitable for studying colorectal and gastric cancers.

Hb0025 is a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts antitumor effects by inhibiting VEGF activity and facilitating T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. Molecular weight: 170.8 KD.